KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) Other Non Operating Income (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Other Non Operating Income for 16 consecutive years, with $2.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Non Operating Income fell 66.5% to $2.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $21.5 million, a 9.6% decrease, with the full-year FY2025 number at $21.5 million, down 9.6% from a year prior.
  • Other Non Operating Income was $2.4 million for Q4 2025 at Halozyme Therapeutics, down from $5.3 million in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $7.3 million in Q4 2024 to a low of -$945000.0 in Q2 2022.
  • A 5-year average of $3.2 million and a median of $3.1 million in 2023 define the central range for Other Non Operating Income.
  • Peak YoY movement for Other Non Operating Income: plummeted 527.6% in 2022, then surged 646.65% in 2023.
  • Halozyme Therapeutics' Other Non Operating Income stood at $331000.0 in 2021, then skyrocketed by 157.4% to $852000.0 in 2022, then skyrocketed by 529.11% to $5.4 million in 2023, then skyrocketed by 35.32% to $7.3 million in 2024, then tumbled by 66.5% to $2.4 million in 2025.
  • Per Business Quant, the three most recent readings for HALO's Other Non Operating Income are $2.4 million (Q4 2025), $5.3 million (Q3 2025), and $6.9 million (Q2 2025).